Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 304 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Erythromycin Clear all
Completed Phase 2 Interventional

Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma

NCT00006219
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
clarithromycin, prasterone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 4, 2011 · Synced Oct 17, 2026, 8:55 AM EDT
Completed Phase 3 Interventional Results available

Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

NCT04677543
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous
Interventions
ALIS, Azithromycin, Ethambutol, ELC
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
27
States / cities
Birmingham, Alabama • Fresno, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 17, 2026, 8:55 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Treatment of Bacterial Vaginosis

NCT00324818
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
metronidazole and azithromycin
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 17, 2026, 8:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants

NCT05965570
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Brensocatib, Clarithromycin
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 17, 2026, 8:55 AM EDT
Terminated Not applicable Interventional Results available

Placebo-Controlled Trial of Antibiotic Therapy in Adults With Suspect Lower Respiratory Tract Infection (LRTI) and a Procalcitonin Level

NCT03341273
View directory record Official record
Conditions
Lower Respiratory Tract Infection
Interventions
Azithromycin, Placebo, VIDAS B.R.A.H.M.S Procalcitonin Test (PCT)
Drug · Other · Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Atlanta, Georgia • Decatur, Georgia • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 17, 2026, 8:55 AM EDT
Completed Not applicable Interventional Results available

Erythromycin in Parkinson's Disease

NCT02005029
View directory record Official record
Conditions
Parkinson's Disease, Levodopa
Interventions
Erythromycin, placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 17, 2026, 8:55 AM EDT
Completed Phase 1 Interventional Results available

A Study of LY2835219 in Participants With Cancer

NCT02117648
View directory record Official record
Conditions
Neoplasm, Neoplasm Metastasis
Interventions
Abemaciclib, Clarithromycin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 17, 2026, 8:55 AM EDT
Recruiting Phase 1Phase 2 Interventional

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

NCT05579366
View directory record Official record
Conditions
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer, Cervical Cancer
Interventions
Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin, Itraconazole
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 17, 2026, 8:55 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP)

NCT00336505
View directory record Official record
Conditions
Pneumonia
Interventions
Cethromycin, Clarithromycin
Drug
Lead sponsor
Advanced Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Woodridge, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 26, 2010 · Synced Oct 17, 2026, 8:55 AM EDT
Completed Phase 1 Interventional

A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS

NCT00000966
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Azithromycin, Pyrimethamine, Leucovorin calcium
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Los Angeles, California • Miami, Florida • Worcester, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2008 · Synced Oct 17, 2026, 8:55 AM EDT
Completed Phase 2 Interventional Results available

Clarithromycin for the Treatment of Hypersomnia

NCT01146600
View directory record Official record
Conditions
Hypersomnia, Idiopathic Hypersomnia, Narcolepsy
Interventions
Clarithromycin followed by placebo, Placebo then Clarithromycin
Drug
Lead sponsor
Lynn Marie Trotti
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 17, 2026, 8:55 AM EDT
Completed Phase 4 Interventional Results available

Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa

NCT00431964
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
azithromycin 250 mg tablets, placebo tablets
Drug
Lead sponsor
CF Therapeutics Development Network Coordinating Center
Network
Eligibility
6 Years to 18 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
31
States / cities
Phoenix, Arizona • Hartford, Connecticut • Atlanta, Georgia + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 17, 2026, 8:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Clarithromycin 500mg Tablets Under Fasting Conditions.

NCT00774644
View directory record Official record
Conditions
Healthy
Interventions
Clarithromycin 500mg
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 18, 2008 · Synced Oct 17, 2026, 8:55 AM EDT
Completed Phase 2Phase 3 Interventional

Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

NCT03672630
View directory record Official record
Conditions
Mycobacterium Avium Complex, Nontuberculous Mycobacterium Infection
Interventions
Azithromycin, Ethambutol, Rifampin
Drug
Lead sponsor
Kevin Winthrop
Other
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
25
States / cities
Loma Linda, California • San Diego, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 17, 2026, 8:55 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Partnership for Rapid Elimination of Trachoma

NCT00792922
View directory record Official record
Conditions
Trachoma
Interventions
Azithromycin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
Up to 5 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
2
States / cities
San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 17, 2026, 8:55 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis

NCT00629941
View directory record Official record
Conditions
Blepharitis
Interventions
AzaSite®
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
2
States / cities
Lewiston, Maine • Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Oct 17, 2026, 8:55 AM EDT
Completed Phase 3 Interventional

Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

NCT04677569
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous
Interventions
ALIS, Azithromycin, Ethambutol, ELC (matching placebo for ALIS)
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
90
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 71 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 17, 2026, 8:55 AM EDT
Completed Phase 1 Interventional

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

NCT00002854
View directory record Official record
Conditions
Cancer
Interventions
filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide, mesna, paclitaxel, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2015
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 17, 2026, 8:55 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Pediatric Taste Test Study of Omnicef Versus Zithromax Antibiotic Suspension Medications

NCT00644774
View directory record Official record
Conditions
Healthy
Interventions
cefdinir (Omnicef), azithromycin
Drug
Lead sponsor
Abbott
Industry
Eligibility
4 Years to 8 Years
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
3
States / cities
Scottsdale, Arizona • St. Petersburg, Florida • Miamiville, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 27, 2008 · Synced Oct 17, 2026, 8:55 AM EDT
Terminated Phase 4 Interventional

KEYS: Study Comparing Clinical Health Outcomes of Telithromycin Versus Azithromycin in Outpatients With Community-acquired Lower Respiratory Tract Infections

NCT00132951
View directory record Official record
Conditions
Respiratory Tract Infections, Chronic Bronchitis, Pneumonia
Interventions
Telithromycin, Azithromycin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 35 Years
Enrollment
2,051 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 27, 2009 · Synced Oct 17, 2026, 8:55 AM EDT
Terminated Phase 3 Interventional Results available

Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection

NCT04341727
View directory record Official record
Conditions
Coronavirus Infection
Interventions
Hydroxychloroquine Sulfate, Azithromycin, Chloroquine Sulfate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 17, 2026, 8:55 AM EDT
Terminated Phase 3 Interventional

Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease

NCT04344444
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Azithromycin
Drug
Lead sponsor
LCMC Health
Other
Eligibility
18 Years to 100 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 17, 2026, 8:55 AM EDT
Completed Phase 3 Interventional

Zmax Pediatric Vs Adult Concentration For The Treatment Of Acute Otitis Media

NCT00360100
View directory record Official record
Conditions
Otitis Media
Interventions
Zmax
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Months to 48 Months
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
2
States / cities
Bardstown, Kentucky • Springfield, Kentucky
Source: ClinicalTrials.gov public record
Updated May 17, 2011 · Synced Oct 17, 2026, 8:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Optimization of the Bowel Preparation Regimen for the PillCam® COLON 2 Capsule Endoscopy Procedure

NCT02481219
View directory record Official record
Conditions
Colorectal Cancer Screening
Interventions
PillCam® COLON 2 procedure-CONTROL, Senna tablets, PEG, Metoclopramide, Erythromycin, SUPREP oral sulfate solution, Bisacodyl, SUPREP oral sulfate solution with Gastrografin
Device · Drug
Lead sponsor
Medtronic - MITG
Industry
Eligibility
50 Years to 75 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Anniston, Alabama • Indianapolis, Indiana • Dayton, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 17, 2026, 8:55 AM EDT